Provided by Tiger Trade Technology Pte. Ltd.

Veru Inc.

2.34
0.0000
Post-market: 2.400.0600+2.56%19:57 EDT
Volume:125.32K
Turnover:291.26K
Market Cap:39.90M
PE:-4.00
High:2.36
Open:2.36
Low:2.29
Close:2.34
52wk High:7.33
52wk Low:2.05
Shares:17.05M
Float Shares:15.48M
Volume Ratio:0.28
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5854
EPS(LYR):-1.5517
ROE:-64.54%
ROA:-54.03%
PB:1.41
PE(LYR):-1.51

Loading ...

Veru Plans Phase 2 Trial of Oral Sabizabulin in Daraxonrasib-Resistant Metastatic Pancreatic Cancer

Reuters
·
Sep 08

Veru - to Advance Oral Sabizabulin for Metastatic Pancreatic Cancer Resistant to Daraxonrasib

THOMSON REUTERS
·
Sep 08

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ Rasonque™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

THOMSON REUTERS
·
Sep 08

Veru CEO Steiner to Join Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Sep 02

Veru Chief Scientific Officer Gary Barnette Acquires $4,841.82 in Common Shares

Reuters
·
Aug 18

Veru Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

Switzerland's MoonLake Q2 Net Loss Narrows as Expenses Fall

Reuters
·
Aug 10

Veru Q3 Net Loss Narrows on Lower G&A Expenses

Reuters
·
Aug 10

Veru Q3 EPS $(0.30) Beats $(0.32) Estimate

Benzinga Earnings
·
Aug 10

Veru FY26 Q3 Net Loss Narrows to $7 Million; R&D Expense Rises 44% to $4.4 Million

Reuters
·
Aug 10

Veru - Phase 2B Plateau Trial Fully Enrolled with 239 Patients

THOMSON REUTERS
·
Aug 10

Veru Q3 EPS USD -0.3

THOMSON REUTERS
·
Aug 10

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2B Plateau Clinical Trial Progress

THOMSON REUTERS
·
Aug 10

Press Release: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b Plateau Clinical Trial Progress

Dow Jones
·
Aug 10

Veru Inc. Expected to Post a Loss of 32 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Veru Wins US Patent Allowance for Enobosarm-Semaglutide Weight-Loss Regimen Claims

Reuters
·
Aug 04

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

THOMSON REUTERS
·
Aug 04

Veru - Interim Analysis Results Expected Q1 2027; Final Topline Data Expected Q4 2027

THOMSON REUTERS
·
Aug 04

Veru Schedules Conference Call on Quarterly Financial Results and Business Update

Reuters
·
Aug 03

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

GlobeNewswire
·
Aug 03